Dyne Therapeutics (DYN) Other Accumulated Expenses (2019 - 2026)

Dyne Therapeutics' Other Accumulated Expenses history runs 8 years deep, the most recent figure standing at $18.0 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 21.56% year-over-year to $18.0 million; the TTM figure through Mar 2026 stood at $18.0 million (up 21.56% YoY), while the FY2025 annual figure was $17.1 million, up 10.93% from the prior year.
• Other Accumulated Expenses was $18.0 million for Q1 2026 at Dyne Therapeutics, up from $17.1 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $26.9 million in Q3 2025 to a low of $3.8 million in Q1 2024.
• Historically, Other Accumulated Expenses has averaged $13.1 million across 5 years, with a median of $12.1 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Other Accumulated Expenses slumped 54.42% in 2023, then surged 285.76% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $11.1 million in 2022, then advanced by 9.23% to $12.1 million in 2023, then rose by 27.06% to $15.4 million in 2024, then advanced by 10.93% to $17.1 million in 2025, then grew by 5.61% to $18.0 million in 2026.
• The last three Other Accumulated Expenses figures came in at $18.0 million (Q1 2026), $17.1 million (Q4 2025), and $26.9 million (Q3 2025), per Business Quant data.